News

Investing.com -- Capricor Therapeutics Inc (NASDAQ: CAPR) stock tumbled 20.4% following news that two top FDA officials overseeing cell and gene therapies have been placed on administrative leave.
Capricor shares four-year data showing Deramiocel slowed DMD progression and preserved function, with maintained safety in long-term use.
Capricor Therapeutics (NASDAQ:CAPR) plunged 32% following a trading halt on Friday after Stat News reported that the new head ...
The agreement grants Weston N.V. access to up to €100 million over a 36-month period following a public listing company's stock. Through a share subscription facility, Weston N.V. will be permitted to ...
Four-year data show preservation of cardiac function, including LVEFSkeletal muscle disease progression continues to slow ...
Cheetah Mobile posted a quarterly loss of 11 cents per share, versus a year-ago loss of 32 cents per share. The company's ...